Global Blood Therapeutics Inc (GBT) Shares Sold by Century Capital Management LLC

Century Capital Management LLC reduced its stake in shares of Global Blood Therapeutics Inc (NASDAQ:GBT) by 33.2% during the first quarter, according to its most recent disclosure with the SEC. The firm owned 119,947 shares of the company’s stock after selling 59,654 shares during the period. Century Capital Management LLC owned approximately 0.28% of Global Blood Therapeutics worth $4,420,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. BlackRock Inc. boosted its stake in shares of Global Blood Therapeutics by 1.6% in the third quarter. BlackRock Inc. now owns 49,739 shares of the company’s stock worth $1,147,000 after buying an additional 775 shares in the last quarter. Artal Group S.A. boosted its stake in shares of Global Blood Therapeutics by 146.1% in the fourth quarter. Artal Group S.A. now owns 246,054 shares of the company’s stock worth $3,555,000 after buying an additional 146,054 shares in the last quarter. Oxford Asset Management boosted its stake in shares of Global Blood Therapeutics by 264.5% in the fourth quarter. Oxford Asset Management now owns 140,845 shares of the company’s stock worth $2,035,000 after buying an additional 102,200 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Global Blood Therapeutics during the fourth quarter worth $10,462,000. Finally, State Street Corp boosted its stake in shares of Global Blood Therapeutics by 1.4% in the fourth quarter. State Street Corp now owns 289,984 shares of the company’s stock worth $4,174,000 after buying an additional 4,024 shares in the last quarter. Institutional investors and hedge funds own 56.36% of the company’s stock.

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Shares of Global Blood Therapeutics Inc (NASDAQ:GBT) traded down 1.65% during trading on Friday, hitting $29.75. 430,733 shares of the stock were exchanged. The stock’s market cap is $1.30 billion. Global Blood Therapeutics Inc has a 12-month low of $13.35 and a 12-month high of $41.15. The stock has a 50-day moving average of $31.03 and a 200 day moving average of $24.09.

Global Blood Therapeutics (NASDAQ:GBT) last announced its quarterly earnings results on Monday, May 1st. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.11. During the same quarter last year, the company posted ($0.56) EPS. Equities analysts predict that Global Blood Therapeutics Inc will post ($2.59) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was first published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://transcriptdaily.com/2017/05/20/global-blood-therapeutics-inc-gbt-shares-sold-by-century-capital-management-llc.html.

A number of analysts recently weighed in on GBT shares. SunTrust Banks, Inc. started coverage on shares of Global Blood Therapeutics in a research note on Monday, April 17th. They set a “buy” rating and a $56.00 price target for the company. Cantor Fitzgerald started coverage on shares of Global Blood Therapeutics in a research note on Wednesday, March 15th. They set an “overweight” rating and a $61.00 price target for the company. Zacks Investment Research cut shares of Global Blood Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, March 16th. Roth Capital set a $47.00 price target on shares of Global Blood Therapeutics and gave the stock a “buy” rating in a research note on Monday, March 20th. Finally, JPMorgan Chase & Co. reiterated a “buy” rating and set a $44.00 price target on shares of Global Blood Therapeutics in a research note on Wednesday, March 15th. One research analyst has rated the stock with a sell rating and eleven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $50.37.

In other news, major shareholder Robert I. Tepper sold 31,225 shares of the business’s stock in a transaction on Thursday, April 6th. The shares were sold at an average price of $33.23, for a total transaction of $1,037,606.75. Following the completion of the transaction, the insider now owns 229,773 shares of the company’s stock, valued at $7,635,356.79. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 6.10% of the company’s stock.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

12 Month Chart for NASDAQ:GBT

Receive News & Ratings for Global Blood Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply